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Abstract
Background
The importance of infectious disease epidemic forecasting and prediction research is underscored by decades of communicable disease outbreaks, including COVID-19. Unlike other
fields of medical research, such as clinical trials and systematic reviews, no reporting guidelines exist for reporting epidemic forecasting and prediction research despite their utility. We
therefore developed the EPIFORGE checklist, a guideline for standardized reporting of epidemic forecasting research.

Methods and findings
We developed this checklist using a best-practice process for development of reporting
guidelines, involving a Delphi process and broad consultation with an international panel of
infectious disease modelers and model end users. The objectives of these guidelines are to
improve the consistency, reproducibility, comparability, and quality of epidemic forecasting
reporting. The guidelines are not designed to advise scientists on how to perform epidemic
forecasting and prediction research, but rather to serve as a standard for reporting critical
methodological details of such studies.

Conclusions
These guidelines have been submitted to the EQUATOR network, in addition to hosting by
other dedicated webpages to facilitate feedback and journal endorsement.

Introduction
The importance of infectious disease epidemic forecasting and prediction research is underscored across decades of communicable disease outbreaks. Epidemic forecasts are valuable for
seasonal pathogens, for example, influenza and dengue [1–3], in addition to international
health public emergencies and other epidemics such as the Zika, chikungunya, and Ebola virus
epidemics [4–9]. Most recently, the Coronavirus Disease 2019 (COVID-19) pandemic has
illustrated the importance of robust, transparent epidemic forecasting and prediction research
for risk communication, decision-making, preparedness, and response [10,11]. Arguably, predictions form an essential part of the scientific method itself [12].
Other fields of medical research, such as clinical trials and systematic reviews, have widely
used study reporting checklists, for example, the CONSORT and PRISMA guidelines [13].
Such checklists improve the interpretation, evaluation, and reproduction by other scientists
and stakeholders, including public health decision-makers, journal editors, and journal
reviewers. Indeed, many journals mandate that reporting checklists are completed prior to
manuscript submission and publication, which has led to demonstrable improvements in
study reporting [14,15]. Although principles for policy-driven communication of models for
neglected tropical disease programs have been discussed [16], a recent systematic review noted
no reporting guidelines exist specifically for epidemic forecasting and prediction research [17].
The need for epidemic forecasting reporting guidelines is underscored by a review of Zika
forecasting and prediction research, which noted methodological reproducibility, accessibility,
and incorporation of uncertainty in these published predictions varied [8].
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To address this gap, we developed the EPIFORGE checklist, the first known set of epidemic
forecasting reporting guidelines. This checklist was developed through a well-established process for developing guidelines for research reporting, involving a Delphi process and broad
consultation with an international panel of infectious disease modelers and model end users
[18,19]. The objectives of these guidelines are to improve the consistency, reproducibility,
comparability, and quality of epidemic forecasting reporting. Here, we describe our guidelines
development process and the resulting checklist. The EPIFORGE checklist is not designed to
advise scientists how to perform epidemic forecasting and prediction research, but rather
serve as a set of standards to ensure critical aspects of these studies are reported in a standardized way.

Methods
We followed health research reporting guideline development best practice as outlined in the
EQUATOR toolkit and by Moher and colleagues [18,19] and summarized in full in the Supporting information (S1 Text). Briefly, The EPIFORGE guideline concept was registered at the
EQUATOR network, and a steering committee (n = 6) formed to develop a guideline development protocol. Members from this steering committee had already identified a case study that
prompted the need for EPIFORGE and conducted a systematic review to ensure no epidemic
forecasting reporting guideline existed [17]. The EPIFORGE steering committee formulated
an initial draft checklist of 20 reporting items during 2 teleconferences. This draft checklist
was the input for an iterative Delphi consensus process. A total of 69 Delphi panelists were
invited, and 46 participated in this process (S1 Table). During 3 initial rounds of Delphi consultations via email (September, October, and December 2019), panelists graded each checklist
item on a scale of 1 through 10 (a score of 1 was defined as “not important,” and a score of 10
was defined as “very important”), with an emphasis on voting based on the concept of the item
(rather than the wording). Checklist items with a mean score 8 were retained for the final
reporting checklist, items with a mean score <5 were dropped, and items with a mean score 5
to 7 were kept for further discussion at a final face-to-face consensus meeting (January 2020).
Additional items were added by Delphi participants during the first 2 email Delphi rounds.

Results
Table 1 presents the final consensus checklist items, including reporting elements on study
goals, data sources, model characteristics and assumptions, model evaluation, and study generalizability. Below, we elaborate and explain each item:

A. Overall study description and goals
Item 1: Describe the study as forecast or prediction research in at least the title or
abstract. These guidelines primarily refer to forecasting research, but the principles are applicable to prediction research more broadly and can be used for these other study types. Forecasting research has been defined as research that “typically offers quantitative statements
about an event, outcome, or trend that has not yet been observed, conditional on data that has
been observed,” whereas prediction research is broader and has been defined as a field, which
“may refer to models that examine the mechanistic drivers of epidemiological characteristics . . ..
as well as studies that estimate epidemiological characteristics with inherent forecasting value,
such as R0” [17]. As the 2 terms may be conflated by studies, we recommend that the study is
described as a forecast or prediction research in at least the title or abstract (for example, [20–
22]). While limiting to the terms “forecast,” “forecasting,” or “prediction” may be too restrictive, we believe that limiting the number of terms is important to enable findability (accurate
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Table 1. EPIFORGE 2020 checklist.
Section of
manuscript

#

Checklist item

Reported on
pagea

Title/Abstract

1

Describe the study as forecast or prediction research in at least the title or
abstract

Introduction

2

Define the purpose of study and forecasting targets

Methods

3

Fully document the methods

Methods

4

Identify whether the forecast was performed prospectively, in real time,
and/or retrospectively

Methods

5

Explicitly describe the origin of input source data, with references

Methods

6

Provide source data with publication, or document reasons as to why this
was not possible

Methods

7

Describe input data processing procedures in detail

Methods

8

State and describe the model type, and document model assumptions, including references

Methods

9

Make the model code available, or document the reasons why this was
not possible

Methods

10 Describe the model validation, and justify the approach

Methods

11 Describe the forecast accuracy evaluation method used, with justification

Methods

12 Where possible, compare model results to a benchmark or other
comparator model, with justification of comparator choice

Methods

13 Describe the forecast horizon, with justification of its length

Results

14 Present and explain uncertainty of forecasting results

Resultsb

15 Briefly summarize the results in nontechnical terms, including a
nontechnical interpretation of forecast uncertainty

Results

16 If results are published as a data object, encourage a time-stamped
version number

Discussion

17 Describe the weaknesses of the forecast, including weaknesses specific to
data quality and methods

Discussion

18 If the research is applicable to a specific epidemic, comment on its
potential implications and impact for public health action and decisionmaking

Discussion

19 If the research is applicable to a specific epidemic, comment on how
generalizable it may be across populations

a

This column refers to where key reporting considerations are included in a manuscript.

b

A break-out box may be a preferred location.

https://doi.org/10.1371/journal.pmed.1003793.t001

returns on searches) in the literature and may assist in standardizing nomenclature across the
field.
Epidemic forecasts may be conflated with projections, simulations, or scenario analyses
[4,10,20], which may or may not be fundamentally different in nature. Here, we refer to forecasts and predictions as predictions of what will happen. Other valuable research focuses on
projections, simulations, or scenario analyses, which can be framed as “what if” scenarios, i.e.,
what would happen conditionally under certain conditions or assumptions (including, for
example, assumptions of no interventions or no control of an epidemic, or assumptions of
long-term seasonality and varied population immunity) [23,24]. Forecasts often refer to more
shorter-term predictions [23]. Many of the reporting principles in this guideline may also be
useful for projections, simulations, or scenario analyses.
Item 2: Define the purpose of study and forecasting targets. Clearly identifying the
research objectives is a fundamental element of any scientific study and is a feature of many
other research reporting guidelines [19]. We recommend that forecasting targets (i.e., each
specific observable outcome being forecasted such as a 2-week-ahead incidence, peak week,
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observation of at least 1 case) should be defined in the introduction section, and, ideally, also
in the abstract (for example, [21,22,25]).
Item 3: Fully document the methods. Methods documentation is essential to any scientific study and follows general best practice for the reporting of other research study types [19].
We recommend that forecasting methods should include a full description of the model that
enables reproducibility, the method of fitting parameters to data (for example, maximum likelihood with function if nonstandard, Bayesian methods), and—where relevant—underlying
epidemic model assumptions (see also Item 8). For example, [20].
Item 4: Identify whether the forecast was performed prospectively, in real time, and/or
retrospectively. We recommend that it is identified whether the forecast was performed prospectively, in real time, and/or retrospectively (for example, [22]). This item is necessary for
interpreting results of forecasting accuracy and may aid in determining whether authors were
blinded to a hold-out set (out-of-sample set) of data used for any model validations. See also
Item 16 for recommendations on time-stamping the results of forecasts.

B. Data description
Item 5: Explicitly describe the origin of input source data, with references. We recommend that the origin of the input source data is provided (for example, [21,26]). This item is
essential for study reproducibility and is a minimum requirement for any manuscript, even if
full study data cannot be publicly shared (see Item 6). For all data types—including laboratory
assay, case counts, demographic data, and nontraditional data streams (for example, internet
event-based data signals)—the authors should include sufficient references to be able to identify the input data [27] and ideally a persistent and unique identifier that resolves to the (meta)
data (for example, [6]).
Item 6: Provide source data with publication, or document reasons as to why this was
not possible. We recommend that source data are made available. Provision of source data
improves forecast reproducibility. Sharing of source data used in forecasts (for example, [1])
facilitates other complementary studies, including those which may independently validate
forecasts and methods. Limitations on data sharing during epidemics is a known challenge
[28]. We are aware of efforts to establish codes of conduct for data sharing during public health
emergencies [29] but recognize the wide range of logistical and other barriers to data sharing
during outbreaks [28,30]. Therefore, we suggest at a minimum reporting of the reasons for not
providing source data with forecast publication. Several major biomedical journals now routinely require authors to provide deidentified data [31]. When data are provided, we recommend inclusion of a data dictionary and/or structured metadata in a standardized format.
Item 7: Describe input data processing procedures in detail. We recommend that the
input data processing procedures are described in detail (for example, [21,22]). This is an
important feature for study reproducibility. Preprocessing procedures may include recoding
and imputation of missing observations, identification and management of extreme outliers
and influential data points, and functional transformations such as data normalization. Provision of data preprocessing code may also be useful.

C. Model characteristics
Item 8: State and describe the model type, and document model assumptions, including
references. We recommend that the model type is stated and described, and the model
assumptions documented (for example, [21,22]). This is critical for study reproducibility, and
it allows interpretation of model output in the context of any assumptions presented. Describing model parameter values and assumptions, with references, further allows other researchers
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to use cited parameter values in their own work (after careful consideration), and this may
expedite forecasting efforts in a public health emergency. For an ongoing epidemic, if the
model makes specific assumptions about current and future interventions and their impact,
they need to be stated with appropriate justification. Model types may include mechanistic or
statistical representation of disease transmission; models may also be classified as stochastic or
deterministic models. These are just some of several classifications of model types [32]. We do
not propose a categorization scheme for model types in these guidelines due to the wide range
of model type nomenclature that is often heterogeneously used by modelers. Developing such
a schema could be the subject of future research.
Item 9: Make the model code available, or document the reasons why this is not possible. We recommend that model code is made available. Providing model code improves
research reproducibility, especially if accompanied by documentation, and may facilitate the
rapid conduct of other studies addressing the same or similar study question(s), especially during a public health emergency. Some forecasting studies already have provided model code
during public health emergencies of international concern [6,33]. Infectious disease modelers
have also made the point that publication of model code may permit direct comparisons of
model performance in real time by external groups [7]. We emphasize that providing model
code is strongly encouraged. There are valid reasons for why researchers may not be able to
provide model code, including possible intellectual property concerns (this potential consideration has been illustrated in the artificial intelligence modeling field more broadly, for example, [34]), or specific concerns about potential misuse (i.e., using the forecasting model as a
“black box” without understanding its principles and limitations). In cases where code is not
made available, we propose that authors provide a brief justification for why this is the case.
This may assist in future studies that seek to identify and mitigate barriers to sharing forecast
model code during public health emergencies. A clear statement of model code availability will
also allow journals to screen submissions for this feature.

D. Model evaluation
Item 10: Describe the model validation, and justify the approach. We recommend
describing the model validation method and justifying the approach. Forecast model validation is critical to ensure accuracy of results and usefulness of models, and it also encourages
trust in the results and methods by other researchers, journal reviewers, journal editors, and
end users. Forecasting research should indicate if cross-validation or out-of-sample validation
was performed, the data used for validation, how many models were considered at each stage
of validation, the time span of validation (with justification), and whether the researchers were
blinded to the external validation dataset (for example, through a prospective design like a
forecast challenge or other real-time forecasting exercise) [2,5,35–37].
Item 11: Describe the forecast accuracy evaluation method used, with justification.
We recommend that the forecast accuracy evaluation method is described and justified. Forecast and prediction research studies may include point predictions (for example, mean number of expected cases) or a full probability distribution of the outcome of interest. It is
important that the metric of validation accuracy is both clearly defined and justified, thereby
allowing forecast performance to be robustly evaluated and compared between studies when
using the same data. Examples include [22].
Item 12: Where possible, compare results to a benchmark or other comparator model,
with justification of comparator choice. We recommend that the forecast results are compared to a benchmark or other comparator model, and the comparator model choice justified.
Benchmark models may include relatively simple models such as autoregression or seasonal
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averages [38]. These comparisons are important to mitigate the risk of model misspecification
and may also provide a “common sense” interpretation of forecast value compared to intuitive
benchmarks such as an autoregression model with a 1-week lag time [39–41]. If there are other
published models for the specific forecasting target or type of target that demonstrate significant improvement compared to simpler models, those forecasts should be used as the comparator to the extent possible [20]. Comparison may include formal statistical comparisons with
established methods (for example, Diebold-Mariano tests or permutation tests) [42,43]. For
emerging pathogens with novel disease traits and novel forecasting targets, such benchmark
models may not be readily available.
Item 13: Describe the forecast horizon, with justification of its length. We recommend
that the forecast horizon is described, and its length justified (for example, [21]). Presenting
forecast accuracy and precision with increasing lead times allows for an evaluation of a forecast’s usefulness over operationally relevant timescales. We suggest justification of the forecast
horizon to avoid inadvertent misrepresentation of model accuracy and precision and to communicate the inherent limits of forecasts that may break down over longer forecast horizons
[38,41].
Item 14: Present and explain uncertainty of forecasting results. We recommend that
uncertainty in the forecasting results is presented and explained. Uncertainty is a fundamental
consideration in developing and interpreting epidemic forecasting and prediction research.
Uncertainty can arise from parameters, assumptions, model choice, lack of knowledge about
the epidemiology of the disease, or variability in the data itself. Qualitative and/or quantitative
estimates of uncertainty can be incorporated into forecasting research through using probabilistic forecast methods, uncertainty intervals around point estimates (for example, prediction
or credibility intervals), sensitivity or scenario analyses, or description of the uncertainty in the
model parameters. We recommend that the estimates of uncertainty are clearly described in at
least the results, and, ideally, also referred to in the discussion and the abstract. Examples
include [20,22].

E. Translation of results for public health practice, interpretability, and
generalizability
Item 15: Briefly summarize the results in nontechnical terms, including a nontechnical
interpretation of forecast uncertainty. We recommend that the results are summarized in
nontechnical terms. Adequately reporting and explaining model forecasts is critical for a wide
range of readers, including public health decision-makers and the media. Forecasts can be misinterpreted, especially when uncertainty is not explicitly and clearly communicated with a
broad audience in mind. We propose that a lack of appropriate communication about these
inherent caveats in forecasting science may lead to skepticism of forecasting by important end
users (such as decision-makers), the media, and the general public. We recommend a brief
nontechnical summary of forecasting research results, as already required by several major
biomedical journals for a range of research fields [44], and including a nontechnical interpretation of forecast uncertainty. Examples include [45,46].
Item 16: If results are published as a data object, encourage a time-stamped version
number. In general, we recommend that results, i.e., the raw forecast data themselves and
summaries of these data, are made available as a public data object. This reporting recommendation serves multiple purposes. First, it allows searching and aggregating of forecast results by
a standardized object nomenclature. Second, it ensures that forecasts are truly prospective,
when claimed to be so. Third, it permits clear communication of when forecasts are updated
(for instance, as parameter estimates are refined, or as new data becomes available). We
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recommend assigning a unique and persistent identifier to the time-stamped and versioned
data object, such as a digital object identifier (DOI). This practice could extend to web-based
forecasting tools linked to the publication also.
Item 17: Describe the weaknesses of the forecast, including weaknesses specific to data
quality and methods. We recommend that the weaknesses in the forecast be described. Limitations can include data quality (for example, heterogeneity in sampling over time and across
populations, diagnostic limitations, or case selection bias), parameter uncertainty, model misspecification, or limitations in generalizability. No model is a complete representation of reality, and much can be gleaned about a forecasting model’s utility from knowing its limitations
or simplifying assumptions. It is important to note that identifying methodological weaknesses
in forecasts does not necessarily mean that they lack credibility. Rather, highlighting such
weaknesses may inform data needs, lead to improvements of forecasts, and assist in interpretation of forecast results during public health decision-making. For example, [22,46].
Item 18: If the forecast research is applicable to a specific epidemic, comment on its
potential implications and impact for public health action and decision-making. When
forecasting research is intended to be applicable to a specific outbreak or epidemic, we propose
that the potential implications of the forecast for that specific epidemic need to be described,
including whether it has a possible impact on public health action or decision-making. Framing the discussion of results in this context is essential for model end users and may assist in
ensuring that model developers are addressing the right research questions from the outset.
For example, [22].
Item 19: If the forecast research is applicable to a specific epidemic, comment on how
generalizable it may be across populations. When forecasting research is intended to be
applicable to a specific outbreak or epidemic, researchers should describe the generalizability
of results between countries, regions, populations, and perhaps even pathogens, together with
the rationale for why (for example, [22]). A forecast’s accuracy or applicability in one setting
may not translate to others due to inherent differences in healthcare capacity, population
demography, disease ecology, socioeconomic factors, and data availability and reliability.

Conclusions
We present the first guidelines for standard reporting of epidemic forecasting research, comprising 19 preferred items in a checklist. We stress that the objectives of these guidelines are
intended to improve the epidemic forecasting reporting consistency and reproducibility, as
well as comparability and quality. They serve as a set of standards to ensure that critical aspects
of these studies are adequately reported and are not intended to advise scientists on how to
perform epidemic forecast and prediction research. We note that our Delphi process also led
to several checklist items, which pertain to the translation of forecasting results for public
health practice.
The primary target audience of these guidelines is scientists using models to forecast infectious disease epidemics as a means to ensure that critical reporting items are included in published manuscripts. While this checklist may also serve as a means of ensuring standardization
of infectious disease modeling quality among this group, it is distinct from other structured
consensus documents, which have focused on modeling principles or made recommendations
for reporting of other types of modeling studies [47–50]. The secondary target audience of
these guidelines include model users (for example, those in operational public health and policy), journal peer reviewers, journal editors, and epidemiology training programs. We encourage formal endorsement by modeling groups and broad adoption by biomedical journals who
already require completion of reporting checklists for manuscript submissions, including
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clinical trials and systematic reviews [51]. While our guidelines were developed with peerreviewed published research papers in mind, these could be applied to epidemic forecasting
research reported elsewhere.
Research reporting guidelines do need to be subfield specific to be pragmatic and useful
(for this reason the EQUATOR website references over 440 guidelines), but it is worth comparing our final guidelines to others medical reporting guidelines, which have been widely
implemented, such as CONSORT and PRISMA [14]. Like EPIFORGE, these guidelines identify the study type, define the study objectives, comment on study limitations, aid in interpreting the validity of the results, and discuss generalizability of the findings.
Our approach to development of this checklist has some limitations. While the major
strength of the EPIFORGE guidelines is the use of a structured Delphi process across a range
of stakeholders, this resulted in a number of valuable reporting considerations suggested by
the Delphi panel, which were not included after the consensus process. We noted several items
suggested by the Delphi panel that were not ultimately voted in. These covered a range of topics and may not be applicable to all forecasting and prediction research. We include these
items as a supporting appendix for general consideration in the field of reporting forecasting
and prediction research, and these may be reconsidered in future versions of the EPIFORGE
reporting guidelines (S2 Table). Future versions should also seek to identify other items which
through a new Delphi process.
While the development process involved broad consultation, we encourage broad and
frank feedback and critique. Feedback will be valuable in updating future iterations of these
guidelines, which are intended to be dynamic and responsive to the ongoing needs of epidemic
forecasters and end users, including those involved in COVID-19 research and response.
These guidelines have been submitted to the EQUATOR Network webpage, in addition to
dedicated webpages to facilitate feedback and journal endorsement ([20–22]; https://
midasnetwork.us/), following examples from other guidelines [14].

Supporting information
S1 Text. Full description of methods.
(DOCX)
S1 Table. Delphi panel members.
(DOCX)
S2 Table. Other reporting considerations not included into the final reporting checklist.
(DOCX)
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